Vaccination of Mice with Replication-Defective Human Immunodeficiency Virus Induces Cellular and Humoral Immunity and Protects against Vaccinia Virus-gag Challenge

Molecular Therapy

Volumn 14, Issue 3, 2006, Pages 432-441

  Baliga, Christopher S ^a   van Maanen, Marc ^a   Chastain, Michael ^b   Sutton, Richard E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

AIDS vaccine; cellular immune response; humoral immune response; replication defective human immunodeficiency virus; vaccinia virus

Indexed keywords

ADENOVIRUS VECTOR; CYCLIN T1; DNA; GAG PROTEIN; GAMMA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LENTIVIRUS VECTOR; PROTEIN ANTIBODY; RNA POLYMERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; AUTOFLUORESCENCE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE CASSETTE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFECTION PREVENTION; MOUSE; NONHUMAN; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS REPLICATION; WILD TYPE;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CYCLINS; CYTOMEGALOVIRUS; GENE PRODUCTS, GAG; GENETIC VECTORS; HIV; HUMANS; IMMUNITY, CELLULAR; MEMBRANE GLYCOPROTEINS; MICE; VACCINATION; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS; MIRIDAE; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 33746927623     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2006.02.021     Document Type: Article

References (49)

1. Piot P., et al. The global impact of HIV/AIDS. Nature 410 (2001) 968-973
2. Nabel G.J. Challenges and opportunities for development of an AIDS vaccine. Nature 410 (2001) 1002-1007
3. Robinson H.L. New hope for an AIDS vaccine. Nat. Rev. Immunol. 2 (2002) 239-250
4. Daniel M.D., et al. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258 (1992) 1938-1941
5. Wyand M.S., et al. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J. Virol. 73 (1999) 8356-8363
6. Almond N., et al. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345 (1995) 1342-1344
7. Johnson R.P., and Desrosiers R.C. Protective immunity induced by live attenuated simian immunodeficiency virus. Curr. Opin. Immunol. 10 (1998) 436-443
8. Baba T.W., et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med. 5 (1999) 194-203
9. Baba T.W., et al. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267 (1995) 1820-1825
10. Hofmann-Lehmann R., et al. Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 17 (2003) 157-166
11. Sawai E.T., et al. Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef. J. Virol. 74 (2000) 2038-2045
12. Chakrabarti L.A., et al. A truncated form of Nef selected during pathogenic reversion of simian immunodeficiency virus SIVmac239Deltanef increases viral replication. J. Virol. 77 (2003) 1245-1256
13. Ruprecht R.M. Live attenuated AIDS viruses as vaccines: promise or peril?. Immunol. Rev. 170 (1999) 135-149
14. Wyand M.S., et al. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70 (1996) 3724-3733
15. Desrosiers R.C., et al. Identification of highly attenuated mutants of simian immunodeficiency virus. J. Virol. 72 (1998) 1431-1437
16. Barouch D.H., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290 (2000) 486-492
17. Amara R.R., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 (2001) 69-74
18. Rose N.F., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106 (2001) 539-549
19. Shiver J.W., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 (2002) 331-335
20. Quinonez R., and Sutton R.E. Lentiviral vectors for gene delivery into cells. DNA Cell Biol. 21 (2002) 937-951
21. Tung F.Y., Rinaldo Jr. C.R., and Montelaro R.C. Replication-defective HIV as a vaccine candidate. AIDS Res. Hum. Retroviruses 14 (1998) 1247-1252
22. Evans D.T., et al. Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239. J. Virol. 79 (2005) 7707-7720
23. Rose N.F., Roberts A., Buonocore L., and Rose J.K. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J. Virol. 74 (2000) 10903-10910
24. Smith S.M., et al. Constitutively dead, conditionally live HIV-1 genomes: ex vivo implications for a live virus vaccine. J. Biol. Chem. 276 (2001) 32184-32190
25. Marzio G., Verhoef K., Vink M., and Berkhout B. In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies. Proc. Natl. Acad. Sci. USA 98 (2001) 6342-6347
26. Xiao Y., et al. Dox-dependent SIVmac with tetracycline-inducible promoter in the U3 promoter region. Virology 269 (2000) 268-275
27. Das A.T., Baldwin C.E., Vink M., and Berkhout B. Improving the safety of a conditional-live human immunodeficiency virus type 1 vaccine by controlling both gene expression and cell entry. J. Virol. 79 (2005) 3855-3858
28. Reif J.S., et al. Epizootic vesicular stomatitis in Colorado, 1982: infection in occupational risk groups. Am. J. Trop. Med. Hyg. 36 (1987) 177-182
29. Schmitz H., Wigand R., and Heinrich W. Worldwide epidemiology of human adenovirus infections. Am. J. Epidemiol. 117 (1983) 455-466
30. Baumann J.G., et al. Murine T cells potently restrict human immunodeficiency virus infection. J. Virol. 78 (2004) 12537-12547
31. Mitchell R.S., et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2 (2004) 1127-1137
32. Schroder A.R., et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110 (2002) 521-529
33. Hacein-Bey-Abina S., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
34. Wu X., Li Y., Crise B., and Burgess S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science 300 (2003) 1749-1751
35. Hazuda D.J., et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305 (2004) 528-532
36. Hazuda D.J., et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287 (2000) 646-650
37. Wu Y., and Marsh J.W. Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science 293 (2001) 1503-1506
38. Wu Y., and Marsh J.W. Early transcription from nonintegrated DNA in human immunodeficiency virus infection. J. Virol. 77 (2003) 10376-10382
39. Matzinger P. The danger model: a renewed sense of self. Science 296 (2002) 301-305
40. Burgess-Beusse B., et al. The insulation of genes from external enhancers and silencing chromatin. Proc. Natl. Acad. Sci. USA 99 Suppl. 4 (2002) 16433-16437
41. Evans D.T., Bricker J.E., and Desrosiers R.C. A novel approach for producing lentiviruses that are limited to a single cycle of infection. J. Virol. 78 (2004) 11715-11725
42. Coskun A.K., and Sutton R.E. Expression of glucose transporter 1 confers susceptibility to human T-cell leukemia virus envelope-mediated fusion. J. Virol. 79 (2005) 4150-4158
43. Wei P., et al. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92 (1998) 451-462
44. Segall H., Yoo E., and Sutton R.E. Characterization and detection of artificial replication-competent lentivirus of altered host range. Mol. Ther. 8 (2003) 118-129
45. Sutton R.E., Reitsma M.J., Uchida N., and Brown P.O. Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1 vectors is cell-cycle dependent. J. Virol. 73 (1999) 3649-3660
46. Casimiro D.R., et al. Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene. J. Virol. 76 (2002) 185-194
47. Fan J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22 (2004) 2993-3003
48. + T cells using an ELISPOT assay. J. Immunol. Methods 181 (1995) 45-54
49. Sutton R.E., et al. Human immunodeficiency virus type 1 vectors efficiently transduce human hematopoietic stem cells. J. Virol. 72 (1998) 5781-5788